Gemcitabine plus celecoxib after pancreatic surgery
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests whether adding celecoxib to gemcitabine chemotherapy after complete (R0) pancreatic tumor removal can lower the chance the cancer comes back. It may help people who have had successful surgery but still need anti-cancer treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- Your pancreatic surgery removed all cancer with clear margins (R0 resection).
- You have not previously used a gemcitabine chemotherapy regimen for other cancers.
- Your general strength is good (performance status score 0 to 2).
- Your blood counts and organ tests are in safe ranges (enough white cells, platelets, and hemoglobin; liver and kidney function not too high/low).
- You can take celecoxib (no true allergy, and you can take it without needing ongoing aspirin or similar anti-inflammatory pain medicines).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new chemotherapy combination after surgery for pancreatic cancer to see if it helps prevent the cancer from coming back. It compares the new treatment to a standard one.
This trial tests if giving a combination of four drugs before and after surgery can help treat pancreatic cancer. The drugs include HRS-4642, gemcitabine, nab-paclitaxel, and adebrelimab. It may help shrink the tumor before surgery and lower the chance of cancer coming back afterward.
This trial tests a combination of an immunotherapy drug (adebrelimab) with chemotherapy before surgery for pancreatic cancer. The goal is to see if this approach can shrink the tumor and improve outcomes for patients whose cancer can be surgically removed.
This trial tests whether adding the diabetes drug canagliflozin to a standard chemotherapy medicine (gemcitabine) can help treat advanced pancreatic cancer. The goal is to see if this combination can shrink tumors or improve survival.
This trial tests whether adding astragalus, an herbal supplement, to the standard chemotherapy drug gemcitabine before surgery can improve outcomes for people with pancreatic cancer. It is a phase 2 study designed to see if the combination is safe and effective.
This study tests whether adding pitavastatin (a cholesterol-lowering drug) to gemcitabine chemotherapy can help treat pancreatic cancer that cannot be surgically removed. You would join if your cancer hasn't grown worse after 2–4 rounds of gemcitabine.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.